** Shares of AI biologics firm Absci Corp ABSI.O rise 3.7% to $3.34 premarket
** Brokerage Needham initiates coverage with a "buy" rating, sets price target of $9
** Brokerage says Absci stands out from the pack due to its practical approach to drug development
** Says unlike many of its peers, Absci generates proprietary, well-annotated, wet-lab data at scale, adds, "It is our view that the real currency for companies focused on drug development in the AI age is the quality of the data used"
** Says co has potential best-in-class assets in high-value therapeutic spaces such as inflammatory bowel disease
** 8 of 8 brokerages rate the stock "buy" or higher; their median PT is $9
** ABSI had fallen 37.6% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.